These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33551226)

  • 1. Safety of reduced anti-thrombotic strategy in patients with HeartMate 3 left ventricular assist device.
    Marshall D; Sanchez J; Yuzefpolskaya M; Sayer GT; Takeda K; Naka Y; Colombo PC; Uriel N; Topkara VK
    J Heart Lung Transplant; 2021 Apr; 40(4):237-240. PubMed ID: 33551226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of reduced anti-thrombotic strategies in HeartMate II patients: A one-year analysis of the US-TRACE Study.
    Katz JN; Adamson RM; John R; Tatooles A; Sundareswaran K; Kallel F; Farrar DJ; Jorde UP;
    J Heart Lung Transplant; 2015 Dec; 34(12):1542-8. PubMed ID: 26277569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early outcomes with durable left ventricular assist device replacement using the HeartMate 3.
    Barac YD; Wojnarski CM; Junpaparp P; Jawitz OK; Billard H; Daneshmand MA; Agrawal R; Devore A; Patel CB; Schroder JN; Milano CA
    J Thorac Cardiovasc Surg; 2020 Jul; 160(1):132-139.e1. PubMed ID: 31740114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term discontinuation of antithrombotic therapy in patients with HeartMate II continuous-flow left ventricular assist device support.
    Schurr JW; Seifert FC; McLarty AJ
    Int J Artif Organs; 2019 Dec; 42(12):770-774. PubMed ID: 31298625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study.
    Saeed O; Colombo PC; Mehra MR; Uriel N; Goldstein DJ; Cleveland J; Connors JM; Najjar SS; Mokadam NA; Bansal A; Crandall DL; Sood P; Jorde UP
    J Heart Lung Transplant; 2020 Jun; 39(6):518-525. PubMed ID: 32340871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First experiences with HeartMate 3 follow-up and adverse events.
    Hanke JS; Dogan G; Rojas SV; Zoch A; Feldmann C; Deniz E; Avsar M; Warnecke G; Haverich A; Schmitto JD
    J Thorac Cardiovasc Surg; 2017 Jul; 154(1):173-178. PubMed ID: 28268010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year outcomes with the HeartMate 3 left ventricular assist device.
    Hanke JS; Dogan G; Zoch A; Ricklefs M; Wert L; Feldmann C; Bara C; Shrestha M; Tillmanns J; Kempf T; Bauersachs J; Haverich A; Schmitto JD
    J Thorac Cardiovasc Surg; 2018 Aug; 156(2):662-669. PubMed ID: 29525258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation.
    Sandner SE; Riebandt J; Haberl T; Mahr S; Rajek A; Schima H; Wieselthaler GM; Laufer G; Zimpfer D
    J Heart Lung Transplant; 2014 Jan; 33(1):88-93. PubMed ID: 24239003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device.
    Dobarro D; Urban M; Booth K; Wrightson N; Castrodeza J; Jungschleger J; Robinson-Smith N; Woods A; Parry G; Schueler S; MacGowan GA
    J Heart Lung Transplant; 2017 Jan; 36(1):42-49. PubMed ID: 27776988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Antiplatelet Therapy During Continuous-Flow Left Ventricular Assist Device Support After Thrombotic Hemorrhagic Events.
    Gallo M; Trivedi JR; Mondal NK; Birks EJ; Slaughter MS
    ASAIO J; 2019; 65(7):683-689. PubMed ID: 30585872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients.
    Boyle AJ; Jorde UP; Sun B; Park SJ; Milano CA; Frazier OH; Sundareswaran KS; Farrar DJ; Russell SD;
    J Am Coll Cardiol; 2014 Mar; 63(9):880-8. PubMed ID: 24316083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective 1-year outcome follow-up in 200 patients supported with HeartMate 3 and HeartWare left ventricular assist devices in a single centre.
    Mueller M; Hoermandinger C; Richter G; Mulzer J; Tsyganenko D; Krabatsch T; Starck C; Stein J; Schoenrath F; Falk V; Potapov E
    Eur J Cardiothorac Surg; 2020 Jun; 57(6):1160-1165. PubMed ID: 32298426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of statin therapy on neurological events following left ventricular assist system implantation in advanced heart failure.
    Vieira JL; Pfeffer M; Claggett BL; Stewart GC; Givertz MM; Coakley L; Mallidi HR; Mehra MR
    J Heart Lung Transplant; 2020 Jun; 39(6):582-592. PubMed ID: 32220561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.
    John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L
    Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of left ventricular assist device implantation on mitral regurgitation: An analysis from the MOMENTUM 3 trial.
    Kanwar MK; Rajagopal K; Itoh A; Silvestry SC; Uriel N; Cleveland JC; Salerno CT; Horstmanshof D; Goldstein DJ; Naka Y; Bailey S; Gregoric ID; Chuang J; Sood P; Mehra MR
    J Heart Lung Transplant; 2020 Jun; 39(6):529-537. PubMed ID: 32279919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the optimal anticoagulation in patients with a left ventricular assist device?
    Rossi M; Serraino GF; Jiritano F; Renzulli A
    Interact Cardiovasc Thorac Surg; 2012 Oct; 15(4):733-40. PubMed ID: 22761118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do patients with the centrifugal flow HeartMate 3 or HeartWare left ventricular assist device have better outcomes compared to those with axial flow HeartMate II?
    Florisson DS; Conte SM; De Bono JA; Newcomb AE
    Interact Cardiovasc Thorac Surg; 2019 Dec; 29(6):844-851. PubMed ID: 31436825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited Efficacy of Thrombolytics for Pump Thrombosis in Durable Left Ventricular Assist Devices.
    Seese L; Hickey G; Keebler M; Thoma F; Kilic A
    Ann Thorac Surg; 2020 Dec; 110(6):2047-2054. PubMed ID: 32348739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous-flow LVAD exchange to a different pump model: Systematic review and meta-analysis of the outcomes.
    Austin MA; Maynes EJ; Gadda MN; O'Malley TJ; Morris RJ; Shah MK; Pirlamarla PR; Alvarez RJ; Entwistle JW; Massey HT; Tchantchaleishvili V
    Artif Organs; 2021 Jul; 45(7):696-705. PubMed ID: 33350485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospitalization Patterns and Impact of a Magnetically-Levitated Left Ventricular Assist Device in the MOMENTUM 3 Trial.
    Vidula H; Takeda K; Estep JD; Silvestry SC; Milano C; Cleveland JC; Goldstein DJ; Uriel N; Kormos RL; Dirckx N; Mehra MR
    JACC Heart Fail; 2022 Jul; 10(7):470-481. PubMed ID: 35772857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.